drug_type
RELEVANT_DRUG
intervention_type
Biological (Cellular therapy, CAR-T)
drug_description
Autologous, gene-modified T cells engineered to express a chimeric antigen receptor targeting GPRC5D on malignant plasma cells; CAR signaling (CD3ΞΆ with costimulation) activates T cells to proliferate, release cytokines, and mediate perforin/granzyme cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor targeting GPRC5D on malignant plasma cells. CAR engagement activates CD3zeta with costimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPRC5D-positive cells.
drug_name
CT071 (autologous GPRC5D-directed CAR-T cells)
nct_id_drug_ref
NCT05838131